Evogene (EVGN) director Sarit Firon details long-dated stock option grants

Rhea-AI Filing Summary

Evogene Ltd. director Sarit Firon filed an initial Form 3 disclosing stock option holdings in the company. The filing lists multiple stock option grants over ordinary shares with exercise prices ranging from 1.2900 to 70.5500 per share and expiration dates between 2026 and 2035. One grant for options over 2,500 ordinary shares at an exercise price of 1.2900 vests in equal quarterly installments of 25%, becoming fully vested on the one-year anniversary of the August 18, 2025 grant date.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Firon Sarit

(Last) (First) (Middle)

14 HAESHEL ST.

(Street)

HERZLIYA 4660643

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Evogene Ltd. [ EVGN ]

3a. Foreign Trading Symbol
[EVGN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	08/10/2020	08/10/2026	Ordinary shares	1,000	$70.55	D
Stock Option (right to buy ordinary shares)	08/10/2021	08/08/2027	Ordinary shares	250	$51.78	D
Stock Option (right to buy ordinary shares)	08/10/2022	08/06/2028	Ordinary shares	250	$29.86	D
Stock Option (right to buy ordinary shares)	08/10/2023	09/23/2029	Ordinary shares	250	$15.95	D
Stock Option (right to buy ordinary shares)	08/10/2024	09/22/2030	Ordinary shares	250	$11.21	D
Stock Option (right to buy ordinary shares)	08/10/2022	09/01/2031	Ordinary shares	3,600	$28.62	D
Stock Option (right to buy ordinary shares)	09/15/2023	09/15/2032	Ordinary shares	3,600	$10.52	D
Stock Option (right to buy ordinary shares)	05/11/2024	05/11/2033	Ordinary shares	3,600	$6.03	D
Stock Option (right to buy ordinary shares)	06/13/2025	06/13/2034	Ordinary shares	3,600	$7.16	D
Stock Option (right to buy ordinary shares)	(1)	08/18/2035	Ordinary shares	2,500	$1.29	D

Explanation of Responses:

1. The options reported in this row vest equally on a quarterly basis (25% per quarter) such that they will be fully vested on the one-year anniversary of the August 18, 2025 grant date.

Remarks:

Exhibit 24.1 - Power of Attorney.

	/s/ Nitsan Deutsch, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Evogene (EVGN) disclose in Sarit Firon’s Form 3 filing?

The Form 3 filing shows director Sarit Firon reporting holdings of multiple stock options over Evogene ordinary shares, with specified exercise prices and expiration dates. It establishes Firon’s initial derivative ownership position as a company insider without indicating any recent purchases or sales.

What stock option grants are reported for Evogene (EVGN) director Sarit Firon?

Sarit Firon reports several stock option grants over Evogene ordinary shares with exercise prices from 1.2900 to 70.5500 per share. The options have expiration dates ranging from 2026 through 2035, reflecting a staggered series of long-dated equity incentives.

How do the lowest-priced Evogene (EVGN) options held by Sarit Firon vest?

The options with a 1.2900 exercise price over 2,500 ordinary shares vest quarterly, at 25% per quarter. They become fully vested on the one-year anniversary of the August 18, 2025 grant date, according to the Form 3 footnote.

Does Sarit Firon’s Evogene (EVGN) Form 3 show any stock purchases or sales?

No explicit buy or sell transactions appear in the data provided. The entries are categorized as holdings of stock options, with transaction codes marked as unknown and no transaction shares reported, indicating disclosure of existing positions rather than new trades.

What is the time span of Evogene (EVGN) option expirations reported for Sarit Firon?

The reported stock options over Evogene ordinary shares have expiration dates ranging from August 10, 2026 to August 18, 2035. This shows Firon’s equity incentives extend across nearly a decade, covering multiple grant years and strike prices.